Relmada Therapeutics, Inc. (FRA:4E2)

Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.38	3.86	4.09	5.4	44.44	2.5
Short-Term Investments	12.5	41.05	92.23	142.93	167.47	114.6
Cash & Short-Term Investments	13.89	44.91	96.32	148.32	211.91	117.09
Cash Growth	-74.34%	-53.38%	-35.06%	-30.01%	80.98%	0.56%
Other Receivables	-	-	-	0.51	0.09	0.08
Receivables	-	-	-	0.51	0.09	0.08
Prepaid Expenses	0.97	0.89	1.19	4.04	11.3	0.9
Total Current Assets	14.85	45.8	97.51	152.87	223.3	118.07
Property, Plant & Equipment	-	-	-	-	-	0
Other Long-Term Assets	0.02	0.02	0.04	0.03	0.03	0.11
Total Assets	14.88	45.82	97.55	152.91	223.33	118.19
Accounts Payable	1.45	4.13	3.51	5.26	11.19	8.35
Accrued Expenses	3.74	6.16	8.69	7.21	3.87	4.26
Total Current Liabilities	5.19	10.29	12.19	12.47	15.06	12.6
Other Long-Term Liabilities	0.22	0	-	-	-	-
Total Liabilities	5.41	10.3	12.19	12.47	15.06	12.6
Common Stock	0.03	0.03	0.03	0.03	0.03	0.02
Additional Paid-In Capital	687.83	676.37	646.23	602.52	513.3	284.88
Retained Earnings	-678.4	-640.88	-560.9	-462.11	-305.07	-179.32
Total Common Equity	9.47	35.52	85.36	140.44	208.26	105.58
Shareholders' Equity	9.47	35.52	85.36	140.44	208.26	105.58
Total Liabilities & Equity	14.88	45.82	97.55	152.91	223.33	118.19
Net Cash (Debt)	13.89	44.91	96.32	148.32	211.91	117.09
Net Cash Growth	-74.34%	-53.38%	-35.06%	-30.01%	80.98%	0.65%
Net Cash Per Share	0.44	1.49	3.20	5.01	12.07	7.51
Filing Date Shares Outstanding	73.33	33.19	30.17	30.1	29.37	16.75
Total Common Shares Outstanding	33.19	30.1	30.1	30.1	27.74	16.33
Working Capital	9.66	35.5	85.31	140.4	208.24	105.47
Book Value Per Share	0.29	1.18	2.84	4.67	7.51	6.46
Tangible Book Value	9.47	35.52	85.36	140.44	208.26	105.58
Tangible Book Value Per Share	0.29	1.18	2.84	4.67	7.51	6.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.